Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902549 | 0.74 | SIGMAR1 (0.43) | TSHRSIGMAR1KDM1ACHRM2CHRM4 | |
| SCHEMBL8865243 | 0.74 | TSHR (0.38) | MAPK1SMN1; SMN2TSHRKDM1A | |
| SCHEMBL769096 | 0.70 | ENPP2 (0.37) | MAPK1TSHRSIGMAR1TP53KDM1A | |
| SCHEMBL6289733 | 0.68 | KDM1A (0.41) | MAPK1SMN1; SMN2TSHRSIGMAR1KDM1A | |
| SCHEMBL19130585 | 0.68 | KDM1A (0.41) | MAPK1SMN1; SMN2TSHRSIGMAR1KDM1A | |
| SCHEMBL9324682 | 0.68 | TSHR (0.35) | TSHR | |
| SCHEMBL3053835 | 0.68 | KDM1A (0.43) | MAPK1SMN1; SMN2TSHRKDM1ACHRM2 | |
| SCHEMBL5796055 | 0.68 | HDAC9 (0.50) | TSHRSIGMAR1ALDH1A1TP53KDM1A | |
| SCHEMBL19130584 | 0.68 | HDAC9 (0.50) | TSHRSIGMAR1ALDH1A1TP53KDM1A | |
| SCHEMBL31511343 | 0.67 | BACE1 (0.37) | MAPK1SMN1; SMN2BACE1SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138179-B2 | Spiro-imidazo compounds | NOVARTIS AG (CH) | 2012-03-20 | — | — | US | disclosed |
| US-20090192145-A1 | Spiro-Imidazo Compounds | SPEEDEL EXPERIMENTA AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192145-A1 | Spiro-Imidazo Compounds | REN, NR3C2, AGTR1 | MAPK1 1385/4885SMN1; SMN2 4484/4885BACE1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.